Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
Potential Registration Trial in Duchenne Muscular Dystrophy on Track to Initiate in First Quarter of 2018
Company to Host Conference Call and Webcast at 4:30 p.m. ET Today
LOS ANGELES, Nov. 29, 2017 -- (Healthcare Sales & Marketing Network) -- Capri... Biopharmaceuticals, FDA Capricor Therapeutics, Duchenne muscular dystrophy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news